ArticleExperimental and therapeutic medicine2023

Rosuvastatin plus ticagrelor decreases the risk of major adverse cardiovascular events and elevates cardiac function compared with ticagrelor alone in patients undergoing percutaneous coronary intervention: A meta‑analysis.

Jinling Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.